For instance, co-administration with EGFR-targeted TKIs or immune checkpoint inhibitors may yield additive or synergistic tumor control by simultaneously targeting CHRM3-driven proliferation and enhancing apoptotic or immune-mediated clearance. This evidence concerns the gene EGFR and neoplasm.